Advertisement

Topics

Operon Biotechnologies, Inc Company Profile

21:07 EST 10th December 2018 | BioPortfolio

Since 1986 Operon Biotechnologies, Inc. has been the global market leader in custom oligonucleotide synthesis driven by the best customer service, consistent quality and cutting edge synthesis and design technologies.
Operon strives to manufacture high-quality products at the best value for our customers — products that our customers have relied upon for 20 years. Operon Biotechnologies' mission is to be the global market leader in custom oligo nucleic acid synthesis, driven by superior customer service, consistent first-rate quality, innovation, and cutting edge technologies.

Location

2211 Seminole Drive
Huntsville
Alabama
35805
United States of America

Contact

Phone: 256-704-8200
Email: oligo-us@operon.com


News Articles [128 Associated News Articles listed on BioPortfolio]

DGAP-Stimmrechte: Elanix Biotechnologies AG (deutsch)

Elanix Biotechnologies AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung DGAP Stimmrechtsmitteilung: Elanix Biotechnologies AG Elanix Biotechnologies AG: Veröf...

DGAP-Gesamtstimmrechtsmitteilung: Elanix Biotechnologies AG (deutsch)

Elanix Biotechnologies AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung DGAP Gesamtstimmrechtsmitteilung: Elanix Biotechnologies AG / Ve.....

Deals this week: SQZ Biotechnologies, Immugenyx, Berkeley Lights

SQZ Biotechnologies has expanded its collaboration with Roche to develop products for oncology indications using cellular therapy. The two companies...Read More... The post Deals this week: SQZ Biotec...

DGAP-Adhoc: Elanix Biotechnologies AG: Widerruf der Bestellung von Herrn Tomas J. Svoboda (CEO) als Vorstandsmitglied (deutsch)

Elanix Biotechnologies AG: Widerruf der Bestellung von Herrn Tomas J. Svoboda (CEO) als Vorstandsmitglied DGAP-Ad-hoc: Elanix Biotechnologies AG / Schlagwort(e): Personalie Elanix Biotechnologies A...

DGAP-Adhoc: Elanix Biotechnologies AG: Frau Professor Laurent-Applegate, Gründerin und Interims-Vorstand, kündigt Verkauf von Aktien der Elanix Biotechnologies AG an (deutsch)

Elanix Biotechnologies AG: Frau Professor Laurent-Applegate, Gründerin und Interims-Vorstand, kündigt Verkauf von Aktien der Elanix Biotechnologies AG an DGAP-Ad-hoc: Elanix Biotechnologies AG / Sc....

INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES

$35.00End Date: Friday Aug-3-2018 5:25:47 PDTBuy It Now for only: $35.00Buy It Now | Add to watch list Biotech365 : INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES BioMarketplace You want to p...

Elanix Biotechnologies: Erfolgreiche Finanzierungsrunde

Ende Mai hat Elanix Biotechnologies eine Kapitalerhöhung angekündigt, heute kommt die Vollzugsmeldung der Berliner. Die Gesellschaft hat fast 0,68 Millionen Aktien ausgegeben. Der Bezugspreis je Ak....

Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for MAXKAFLEN®. Hoverink Biotechnologies, Inc plans to develop and commercialize MAXKAFLEN® a cattle and swine antibiotic.

Overview LOS ANGELES, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- On September 26, 2018 We filed trademark applications covering: MAXKAFLEN® Word Mark               MAXKAFLEN Goods and...

Drugs and Medications [0 Results]

None

PubMed Articles [61 Associated PubMed Articles listed on BioPortfolio]

Rv1460, a SufR homologue, is a repressor of the suf operon in Mycobacterium tuberculosis.

Iron-sulphur (Fe-S) clusters are ubiquitous co-factors which require multi-protein systems for their synthesis. In Mycobacterium tuberculosis, the Rv1460-Rv1461-Rv1462-Rv1463-csd-Rv1465-Rv1466 operon ...

Reciprocal enhancement of gene expression between the phz and prn operon in Pseudomonas chlororaphis G05.

In previous studies with Pseudomonas chlororaphis G05, two operons (phzABCDEFG and prnABCD) were confirmed to respectively encode enzymes for biosynthesis of phenazine-1-carboxylic acid and pyrrolnitr...

Regulation of the gyr operon of Mycobacterium tuberculosis by overlapping promoters, DNA topology, and reiterative transcription.

DNA gyrase introduces negative supercoils into DNA to maintain topological homeostasis. The genes encoding gyrase, gyrB and gyrA, form a dicistronic operon in Mycobacterium tuberculosis (Mtb) and othe...

Mutation in cyl operon alters hemolytic phenotypes of Streptococcus agalactiae.

Streptococcus agalactiae infects numerous fish species, causing considerable economic losses during fish cultivation. This study compared the phenotypic differences among S. agalactiae hemolytic varia...

The C. difficile clnRAB operon initiates adaptations to the host environment in response to LL-37.

To cause disease, Clostridioides (Clostridium) difficile must resist killing by innate immune effectors in the intestine, including the host antimicrobial peptide, cathelicidin (LL-37). The mechanisms...

Clinical Trials [0 Results]

None

Companies [105 Associated Companies listed on BioPortfolio]

Operon Biotechnologies, Inc

Since 1986 Operon Biotechnologies, Inc. has been the global market leader in custom oligonucleotide synthesis driven by the best customer service, consistent quality and cutting edge synthesis and des...

RAN Biotechnologies

Based in Beverly, MA, USA, RAN Biotechnologies, Inc., www.ranbiotechnologies.com, provides chemicals specially optimized for microfluidic and biotechnological applications. Partic...

Open Therapeutics

Open Therapeutics (http://OpenTherapeutics.org) is a crowdsourcing life science firm that creates and attracts therapeutic biotechnologies and crowdsources them for the global ...

Genemed Biotechnologies Incorporated

Genemed Biotechnologies Inc. provides high quality contract manufacturing services for a wide variety of research and diagnostic products including native or recombinant proteins and nucleotides

NEXGEN Biotechnologies, Inc.

NEXGEN Biotechnologies, Inc. is the specialized 2nd Generation Plant Biotechnology company begun firstly in Korea.NEXGEN Biotechnologies, Inc., established in November 1999, is the venture biotechnolo...

More Information about "Operon Biotechnologies, Inc" on BioPortfolio

We have published hundreds of Operon Biotechnologies, Inc news stories on BioPortfolio along with dozens of Operon Biotechnologies, Inc Clinical Trials and PubMed Articles about Operon Biotechnologies, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Operon Biotechnologies, Inc Companies in our database. You can also find out about relevant Operon Biotechnologies, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record